25/05/2026 – Following release of 2025 results and securing of clinical trial insurance policy, Maxim Group reiterates its buy recommendation on AB Science’s stock with a target price of EUR 4.0 per share Download PDF Post navigationPreviousPrevious post:Annual financial results as of 31 December, 2025NextNext post:Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per shareRelated PostsAB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026Annual financial results as of 31 December, 202513 May 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026
